AVI Biopharma Gets $18M Flu Contract

6/7/10

AVI Biopharma (NASDAQ: AVII), the Bothell, WA-based developer of RNA-based therapies, said today it has been awarded a U.S. defense contract that could be worth as much as $18 million to develop a treatment against pandemic H1N1 flu. The money is supposed to support development of AVI-7100 as a nasal spray formulation, and to pay for initial human trials to demonstrate safety.

By posting a comment, you agree to our terms and conditions.